# Mitochondrial epigenetic mechanisms in cancer: an updated overview

**Authors:** Andrea Stoccoro, Fabio Coppedè

PMC · DOI: 10.3389/fcell.2025.1720652 · Frontiers in Cell and Developmental Biology · 2026-01-12

## TL;DR

This review discusses how changes in mitochondrial epigenetics contribute to cancer development and treatment resistance.

## Contribution

The paper provides an updated overview of mitochondrial epigenetic mechanisms and their role in cancer.

## Key findings

- Mitochondrial DNA methylation and non-coding RNAs are key mitoepigenetic mechanisms in cancer.
- Bidirectional epigenetic communication between the nucleus and mitochondria influences tumor progression.
- Mitoepigenetic alterations are linked to cancer pharmacoresistance and could be targeted therapeutically.

## Abstract

Mitochondria are central organelles in regulating apoptosis, cellular metabolism, metabolite biosynthesis, energy production, and overall cellular homeostasis. Over the past years, abundant evidence has shown that mitochondrial dysfunction and the resulting metabolic reprogramming profoundly influence key hallmarks of tumor development, including initiation, progression, angiogenesis, and metastasis, playing a role also in therapeutic resistance. Consequently, mitochondria have emerged as a promising target for anticancer therapy. Beyond well-known mutational abnormalities in the mitochondrial genome, recent studies indicate that altered mitochondrial epigenetic mechanisms could also contribute to cancer etiology. In the current review, we present a brief, up-to-date overview of the literature on mitochondrial epigenetic regulation in cancer. We will focus on the main characterized mitoepigenetic mechanisms, namely mitochondrial DNA (mtDNA) methylation and activity of mtDNA-encoded non-coding RNAs. We also consider bidirectional epigenetic crosstalk between the nucleus and mitochondria, whereby metabolites and signaling pathways coordinate chromatin states and mitochondrial function. Collectively, available evidence links mitoepigenetic alterations to tumor progression and pharmacoresistance, nominating these pathways as tractable targets for pharmacological intervention.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Diseases:** metastasis (MESH:D009362), mitochondrial dysfunction (MESH:D028361), cancer (MESH:D009369)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12832663/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12832663/full.md

## References

82 references — full list in the complete paper: https://tomesphere.com/paper/PMC12832663/full.md

---
Source: https://tomesphere.com/paper/PMC12832663